RadNet, Inc.
RadNet provides outpatient diagnostic imaging services in the US through two segments: Imaging Centers and Artificial Intelligence. Services include MRI, CT, PET, nuclear medicine, mammography, ultrasound, and others. The company also develops and sells digital image systems, PACS, and AI suites for radiologist interpretation and prostate cancer screening. Founded in 1981 and headquartered in Los Angeles, California.
Overview
Strengths
- High-quality earnings: over the last 6 years, free cash flow added up to 4,099% of reported net income.
- Consistent growth: revenue has compounded at 13.7% a year over 5 years, rising every year.
Weaknesses
- Shareholder dilution: the share count has grown by 10.3% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Heavy interest burden: interest expense absorbs 69% of operating profit.
- Our discounted cash flow target price (9.48 USD) is 88% below the current price.
- Valued at a premium to its Diagnostics & Research peers: P/FCF 70.6x vs. a median of 24.1x.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data